Company

Portfolio Data

Back to Company Search

EVIDENCE-BASED PRACTICE INSTITUTE, INC.

Address

7241 36TH AVE SW
SEATTLE, WA, 98126-3218
USA

View website

UEI: PP5RSVPSBJD5

Number of Employees: 24

HUBZone Owned: No

Woman Owned: Yes

Socially and Economically Disadvantaged: No

SBIR/STTR Involvement

Year of first award: 2011

Phase I Awards

Phase II Awards

100%

Conversion Rate

$2,473,790

Phase I Dollars

$10,651,451

Phase II Dollars

$13,125,241

Total Awarded

Awards

Up to 10 of the most recent awards are being displayed. To view all of this company's awards, visit the Award Data search page.

iKinnect Mobile Technology to Reduce Teen Substance Misuse and Health Disparities

Amount: $1,312,919 Topic: NIDA

PROJECT SUMMARY/ABSTRACT Adolescent substance abuse (SA) has been called America’s #1 public health problem, affecting as many as 16% of all youth under age 18 and often resulting in serious consequences such as criminal involvement, health problems, and suicide. Given that adolescent SA is associated with high rates of comorbidity with mental health (MH) problems and increased suicide risk, integrated SA-MH treatment involving cognitive- behavioral and family therapy-based approaches, as well as early intervention, is critical. Yet few adolescents receive any treatment for SA, and unmet needs for services are likely to increase following COVID-19-related stressors, which disproportionately affected Black, Indigenous, and other youth of color. Developing culturally- appropriate mobile app technology to effectively address adolescent SA, MH symptoms, and suicide risk, delivering it in novel universal settings, and using direct-to-consumer and family peer support specialist techniques could potentially have a large-scale and highly cost-effective public health impact. iKinnect is a paired mobile app platform that supports parents (in delivering) and youth (in receiving) evidence-based practices to reduce youth problem behaviors. Based on Multisystemic Therapy principles, iKinnect1.0 was originally designed to help youth with serious conduct problems. Results from a randomized controlled trial (RCT; N=72) demonstrated its efficacy in reducing externalizing behaviors and improving parenting effectiveness in youth with serious conduct disorder. iKinnect is currently being adapted for more severely disordered suicidal youth involved in the juvenile justice system as well as their parents. We now seek to significantly adapt iKinnect for use with a general population of teens with problematic substance use and their parents to reduce SA, its harmful effects, opioid overdoses, and progression to substance use disorders, as well as other behavioral health problems that are exacerbated by SA and/or interfere with SA treatment. This 34-month fast track seeks to address SA and co-occurring MH problems in teens by significantly adapting iKinnect to deliver evidence-based SA and MH interventions to general-population youth engaging in SA. We will pursue regulatory pathways for iKinnect-SA as a mobile medical device to achieve Food and Drug Administration (FDA) approval by the project’s end to pave the way for successful Phase III commercialization. The proposal is defined by three project stages which include: (1) a proof-of-concept formative evaluation stage where we will iteratively design, test, and build a prototype (Phase I; Months 1-10); (2) a product design-and-build formative evaluation stage, where we will design, build, and test all remaining features and apps (Phase II; Months 11-22); and (3) a summative evaluation stage involving a pilot test (N=25 dyads) and a RCT (N=300 dyads) comparing iKinnect-SA to an enhanced condition that combines iKinnect-SA with Peer Support Specialists and an active control condition app (Phase II; Months 23-34).

SBIR

Phase II

2024

HHS

NIH

iKinnect Mobile Technology to Reduce Teen Substance Misuse and Health Disparities

Amount: $319,737 Topic: NIDA

PROJECT SUMMARY/ABSTRACTAdolescent substance abuse (SA) has been called America’s #1 public health problem, affecting as many as 16% of all youth under age 18 and often resulting in serious consequences such as criminal involvement, health problems, and suicide. Given that adolescent SA is associated with high rates of comorbidity with mental health (MH) problems and increased suicide risk, integrated SA-MH treatment involving cognitive- behavioral and family therapy-based approaches, as well as early intervention, is critical. Yet few adolescents receive any treatment for SA, and unmet needs for services are likely to increase following COVID-19-related stressors, which disproportionately affected Black, Indigenous, and other youth of color. Developing culturally- appropriate mobile app technology to effectively address adolescent SA, MH symptoms, and suicide risk, delivering it in novel universal settings, and using direct-to-consumer and family peer support specialist techniques could potentially have a large-scale and highly cost-effective public health impact.iKinnect is a paired mobile app platform that supports parents (in delivering) and youth (in receiving) evidence-based practices to reduce youth problem behaviors. Based on Multisystemic Therapy principles, iKinnect1.0 was originally designed to help youth with serious conduct problems. Results from a randomized controlled trial (RCT; N=72) demonstrated its efficacy in reducing externalizing behaviors and improving parenting effectiveness in youth with serious conduct disorder. iKinnect is currently being adapted for more severely disordered suicidal youth involved in the juvenile justice system as well as their parents. We now seek to significantly adapt iKinnect for use with a general population of teens with problematic substance use and their parents to reduce SA, its harmful effects, opioid overdoses, and progression to substance use disorders, as well as other behavioral health problems that are exacerbated by SA and/or interfere with SA treatment.This 34-month fast track seeks to address SA and co-occurring MH problems in teens by significantly adapting iKinnect to deliver evidence-based SA and MH interventions to general-population youth engaging in SA. We will pursue regulatory pathways for iKinnect-SA as a mobile medical device to achieve Food and Drug Administration (FDA) approval by the project’s end to pave the way for successful Phase III commercialization. The proposal is defined by three project stages which include: (1) a proof-of-concept formative evaluation stage where we will iteratively design, test, and build a prototype (Phase I; Months 1-10); (2) a product design-and-build formative evaluation stage, where we will design, build, and test all remaining features and apps (Phase II; Months 11-22); and (3) a summative evaluation stage involving a pilot test (N=25 dyads) and a RCT (N=300 dyads) comparing iKinnect-SA to an enhanced condition that combines iKinnect-SA with Peer Support Specialists and an active control condition app (Phase II; Months 23-34).

SBIR

Phase I

2023

HHS

NIH

iKinnect2.0 for Juvenile Justice Involved Youth at Risk for Suicide Diversity Supplement

Amount: $1,825,401 Topic: NIMH

PROJECT SUMMARY/ABSTRACTSuicidal behaviors (ideation, planning, attempts) and non-suicidal self-injurious behaviors (NSSI) are highly prevalent among juvenile justice-involved transition-age (TA) youth. More than half of youth in the juvenile justice (JJ) system report suicidal ideation; one-third report a history of suicidal behavior. Black youth are disproportionately represented in juvenile justice and are also at increased risk of suicide, as rates of suicidal behavioral and death by suicide among Black youth have risen at an alarming rate, faster than other racial/ethnic groups. This increase has resulted in a number of government initiatives to increase suicide prevention efforts for Black youth. Reducing suicide risk among JJ-involved youth must occur in conjunction with interventions addressing their broader needs for reduced externalizing behavior and in ways that are culturally appropriate for Black youth.iKinnect is a paired mobile app platform that supports parents (in delivering) and youth (in receiving) evidence-based practices to reduce youth problem behaviors. Based on Multisystemic Therapy principles, iKinnect1.0 was originally designed to help youth with serious conduct problems. Results from a randomized controlled trial (RCT; N=72) demonstrated its efficacy in reducing externalizing behaviors and improving parent effectiveness. This fast-track proposal seeks to significantly expand iKinnect to prevent NSSI, suicidal behaviors (ideation, planning, attempts), and death by suicide in JJ-involved TA youth while continuing to decrease externalizing behaviors and prevent recidivism. Leaders in the area of suicide risk among Black youth and cultural appropriateness of interventions will guide these efforts.This 33-month fast track will include three primary phases of evaluation: (1) a proof-of-concept formative evaluation phase during which we will iteratively design, test, and build a central portion of iKinnect2.0 to achieve its usability, acceptability, and relevance (Months 1-10); (2) a product design-and-build formative evaluation phase, where we will design, build, and test all remaining features for iOS and Android phones, while also preparing the platform for clinical use (Months 11-23); and (3) a summative evaluation phase involving a pilot test (N=15) of iKinnect2.0 and an RCT (N=120) comparing iKinnect2.0 to an active control condition; and results will then be analyzed, reported, and disseminated (Months 24-33). We predict that iKinnect2.0 TA youth and parents will report a significantly greater decrease in suicidal and NSSI behaviors and in conduct problem behaviors in TA youth. Furthermore, iKinnect2.0 participants (TA youth and parents) will report significantly greater use of behavioral skills, as well as self-efficacy in coping with emotional distress and other challenging situations. iKinnect2.0 parents will report greater awareness of and confidence in applying evidence-based strategies to prevent suicide/NSSI and support their suicidal youth through a suicide crisis.

SBIR

Phase II

2022

HHS

NIH

Treating Drivers of Suicide in Primary Care using Jaspr Health

Amount: $1,834,686 Topic: 350

PROJECT SUMMARY/ABSTRACTSuicide remains a serious public health problem in the U.S. as rates have risen nearly each year since 2005, from 11.0 per 100,000 to 14.8 per 100,000 in 2018, totaling 48,344 in 2018; 1.4 million U.S. adults made a suicide attempt, and another 12 million thought seriously about killing themselves that same year. Alcohol use disorder (AUD) exponentially increases suicide risk and can also interfere with suicide prevention intervention efforts. Suicide prevention initiatives over the past decade have targeted healthcare systems (HCS) in general and primary care clinics (PCC) in particular because so many who die by suicide access their primary care provider (PCP) in the months and year prior to their death. Though universal suicide screening is now routinely conducted in PCC, many HCS and PCC struggle to provide suicide prevention evidence-based practices (EBP) on par with other behavioral health EBP commonly treated in PCC. Digital technologies can efficiently and reliably help deliver suicide prevention EBP in PCC and increase the confidence and competence of PCP in treating suicide, including AUD that may interfere with these efforts.Jaspr Health (“Jaspr”; R44MH108222) is a suicide prevention platform originally designed for use by acutely suicidal patients in emergency departments (ED) to deliver suicide prevention EBP. Grounded in Jobes’ Collaborative Assessment and Management of Suicidality (CAMS), Jaspr guides patients in completing a comprehensive suicide risk assessment and lethal means counseling, builds a crisis stabilization plan, and teaches behavioral skills to reduce imminent distress; videos of people with live experience (PLE) offer wisdom and hope for getting through suicide crises. Information is summarized for the care team to aid in discharge disposition planning. A companion app provides support post-discharge. Results from a randomized controlled trial (RCT; N=31) comparing Jaspr to Care-as-Usual strongly support its feasibility, acceptability, and effectiveness in increasing delivery of EBP, reducing agitation and distress, improving capacity to cope with suicidal thoughts, and improving ED satisfaction.This 34-month fast track seeks to increase the public health impact of Jaspr Health by extending its utility to deliver evidence-based brief interventions that directly target and treat a person’s reasons for wanting to die (their “drivers” for suicide) while simultaneously addressing alcohol misuse. The proposal is defined by three project stages which include: (1) a proof-of-concept formative evaluation stage where we will iteratively design, test, and build a prototype (Phase I; Months 1-10); (2) a product design-and-build formative evaluation stage, where we will design, build and test all remaining features and apps (Phase II; Months 11- 22); and (3) a summative evaluation stage involving a pilot test (N=20) and a RCT (N=120) comparing Jaspr to a suicide prevention app and other online wellness resources (Phase II; Months 23-34).

SBIR

Phase II

2022

HHS

NIH

iKinnect2.0 for Juvenile Justice Involved Youth at Risk for Suicide

Amount: $957,530 Topic: 104

SBIR

Phase I

2021

HHS

NIH

Treating Drivers of Suicide in Primary Care using Jaspr Health

Amount: $397,990 Topic: 350

SBIR

Phase I

2021

HHS

NIH

CAMS Relational Agent System (CAMS-RAS) for Suicide Prevention

Amount: $2,879,146 Topic: 104

PROJECT ABSTRACTOver 44,000 people die annually by suicide in the United States (US) making suicide the 10th leading cause of death overall and the second leading cause of death among those 10-44. In addition, 9.8 million adults contemplate suicide annually, and one million will make a suicide attempt. From 2006 to 2013, the rate of ED visits for suicidal ideation among adults increased by 12% on average annually. While millions are devoted annually to prevent suicide, suicide rates are rising in the US. Our ultimate aim is to reduce deaths by suicide while also reducing unnecessary hospitalization, emergency department (ED) and hospital readmissions, and stop the revolving-door of acute crisis care through the use of innovative technologies.In Phase I, we proposed to: (1) develop and scientifically validate an avatar for use by suicidal ED patients that delivers the Collaborative Assessment and Management of Suicidality (CAMS), an efficacious and cost-effective intervention developed by David Jobes, PhD; and (2) to design clinical support tools and Just-in- Time training for use by ED medical providers to enhance their delivery of an evidence-based suicide protocol and facilitate an evidence-based approach to discharge disposition. Our work was also guided by Phase I reviewers’ concerns. We fully met and exceeded project aims. Most notably, we created a 15-minute avatar (“Dr. Dave”) who performed a portion of the CAMS Suicide Status Interview which was well-liked and described as helpful by suicidal ED patients who interacted with “Dr. Dave.”In Phase II, we propose to complete the development of Virtual CAMS patient and provider tools and to ready it for EHR integration into EPIC. We will again use an agile process of development and seek feedback from target end-users. A diverse group of advisors will consult to us to ensure product excellence and readiness for commercialization. To ensure thorough testing of the product’s provider and patient tools, we will use a two-condition, randomized study to evaluate Virtual CAMS’ efficacy in preventing suicidal behaviors and inappropriate/unnecessary hospital admissions, and improving self-efficacy for coping with acute distress.PROJECT NARRATIVE: PUBLIC HEALTH RELEVANCE Suicide is the tenth leading cause of death among Americans of all ages and the second leading cause of death for those 10-44, with 44,965 suicides occurring in the U.S. in 2016 – one suicide every 11.7 minutes. The Collaborative Assessment and Management of Suicidality (CAMS) is an evidence-based, cost- effective, suicide-specific intervention that facilitates engagement, assessment, and treatment of suicidal risk. Virtual CAMS seeks to facilitate the delivery of CAMS and other evidence-based procedures to reduce suicide during and after the ED visit to reduce suicide.

SBIR

Phase II

2018

HHS

NIH

Using Mobile Technology to Enhance MST Outcomes

Amount: $1,525,654 Topic: 104

PROJECT SUMMARY ABSTRACTEach yearover one million adolescents are arrestedmany more engage in other serious conduct problemsincluding binge drinkingillicit drug useand school drop outCollectivelythese problems result in enormous costs to individualsfamiliesand societyThe most effective interventions to address these problems are family basedwith a strong clinical emphasis on helping parents better manage youth behavior through increased monitoring of activitiesconsistent use of contingencies to reward appropriate behaviorand enhancing intrinsic motivation toward prosocial behaviorAlthough empirically supported treatmentsESTslike Multisystemic TherapyMSTexistthey are expensive and time intensivethus limiting their public health impactWe seek to developevaluateand commercialize a linked parent youth mobile app systemVillageWhereVWto support the key treatment targets of EBTs for this populationclear parental expectationsparental monitoringdiscipline consistencyand parental supportwhile simultaneously cultivating intrinsic motivation in youth toward prosocial behaviorsWhen used in conjunction with an EST for delinquent youthVW could help reduce treatment length and costWhen provided in non EST clinical settingsVW may increase access to state of the art clinical techniques to those who might not otherwise receive themIn Phase Iwe developed and tested the usabilityacceptabilityand feasibility of VW with serious juvenile offenders and their parents receiving MSTProof of concept was determined in two phasesa formativeevaluationto test usability and acceptability with feedback from target end users and stakeholdersand a summative evaluationto test feasibility in a four week within subjects pilot study where parent youth dyads used VWConsistent with initial hypothesesVW was well liked by parents and teensrated as usefulimproved parental management practicesand reduced parental stressIn Phase IIwe propose to accomplish the following aimscomplete the development of VW by expanding its featuresincluding creating an iPhone version of VW to expand its reach and impactcreatean advisory board to guide additional features and processes to ensure its usabilityacceptabilityandreadiness for commercial success in Phase IIIconduct usability and acceptability tests of all new features for all target end usersandconduct aweek randomized controlled trial comparing VW to an attention control mobile app to evaluate its effectiveness across four time points withparent youth dyads across the spectrum of clinically significant conduct disorder severityIn comparison to study controlswe expect VW will significantly increase parental structuring of youth behaviorparental monitoringgreater effectiveness and consistency in providing rewards for meeting expectationsparenting efficacyand warm parent youth communicationand will decrease parent report of life stress as well as youthsexternalizing behaviorsincluding reports of delinquent and substance using behaviors

SBIR

Phase II

2017

HHS

NIH

CAMS Relational Agent System (CAMS-RAS) for Suicide Prevention

Amount: $274,259 Topic: 104

DESCRIPTION provided by applicant Every minutes someone in the United States U S chooses to end his or her life resulting in over suicides in the US each year The economic cost of suicide in the U S was $ billion annually in when adjusted for present day inflation the economic toll rises to $ billion The combined cost of medical and work loss is estimated at $ billion annually In people were treated in EDs for self inflicted injuries Beginning in with the Surgeon Generalandapos s Call to Action to Prevent Suicide millions have been devoted annually both publicly approximately $ million from NIH and privately approximately $ million from American Foundation for Suicide Prevention to prevent suicide Yet despite this significant and sustained effort there is no evidence of a decrease in suicides or suicide attempts in the U S Our overarching goal is to create a tool that could reduce suicide rates increase delivery of efficacious suicide interventions and decrease overall costs associated with suicidal behaviors With this in mind we intend to develop and scientifically validate a relational agent for suicidal patients that delivers Collaborative Assessment and Management of Suicidality CAMS an efficacious and cost effective intervention developed by David Jobes PhD and to create an integrated software system CAMS Relational Agent System CAMS RAS that assists medical personnel by synthesizing the CAMS intervention findings into an easy to interpret report and providing empirically derived clinical decision support integrates into the health care systemandapos s electronic health record EHR enhances the patientandapos s coping capability by including psychoeducational skills training modules for use during and after hospitalization and automates the delivery of caring contacts an efficacious and brief suicide prevention intervention provided after discharge Our initial target will be EDs as they are often the initial point of contact and where personnel must make the decision whether to hospitalize or discharge the suicidal patient We will also conduct testing in other medical and outpatient mental health settings to ensure public health impact and commercial success Phase I project aims include creating an advisory board to guide the development of CAMS RAS iteratively design and develop relational agent andquot Dr Daveandquot modeled after the gestures expressions and mannerisms of CAMS treatment developer David Jobes PhD and conduct feasibility tests to determine whether CAMS RAS is acceptable easy to use and liked by target end users acutely suicidal patients admitted to hospital EDs psychiatric inpatient units and medical floors for treatment of injuries sustained during a suicid attempt hospital medical personnel administrators and other stakeholders including peer advocates and outpatient suicidal patients clinicians and administrators PUBLIC HEALTH RELEVANCE Suicide is the tenth leading cause of death among Americans of all ages Over suicides occurred in the U S in one suicide every minutes In the same year over a million U S adults reported attempting suicide were treated in emergency departments EDs for self inflicted injuries and were hospitalized The cost of suicidal behaviors in the U S was $ billion in The Collaborative Assessment and Management of Suicidality CAMS is an evidence based cost effective suicide specific intervention that facilitates engagement assessment and treatment of suicidal risk Unfortunately most ED and outpatient mental health clinicians do not know CAMS and lack knowledge in how to effectively assess and intervene with suicidal individuals The CAMS Relational Agent System seeks to facilitate the delivery of CAMS and other evidence based procedures to reduce suicide

SBIR

Phase I

2016

HHS

NIH

PracticeGround: Transforming Training and Delivery of Mental Health EBPs

Amount: $1,273,645 Topic: 104

DESCRIPTION provided by applicant Mental disorders affect million Americans and result in an annual loss of $ billion and total costs of at least $ billion While numerous psychosocial empirically supported therapies ESTs exist few clinicians are adequately trained to deliver them The overarching goal of this project is to develop a comprehensive software solution that effectively and efficiently facilitates the delivery of psychosocial ESTs for mental health problems To ensure significant reach and public health impact Practice Ground will be designed using industry standards for commercial success Specifically Practice Ground will be built as a third party module that seamlessly integrates into electronic health records EHRs and optimizes usersandapos workflow Practice Ground aids delivery of ESTs by integrating the following components dynamic progress monitoring clinical decision support rich visual displays of client outcomes online training modules in ESTs just in time training for guided real time assistance in delivering ESTs educational videos and a client portal In Phase I we developed and tested the usability acceptability and feasibility of an online progress tracker OPT prototype OPT was specifically selected because of its design and workflow complexities We also adapted an existing training course on progress monitoring PM to an online training format Proof of concept was determined in two phases extensive feedback from target end users clinicians clients and other stakeholders clinic directors program managers throughout software development formative evaluation and a within subjects pilot study N of the final prototype summative evaluation Consistent with initial hypotheses OPT significantly increased progress monitoring over time and significantly reduced barriers to use In addition we self funded continued work on OPT for a second year andquot Phase I Aandquot in order to complete a commercial ready HIPAA compliant product for launch in July We met and exceeded original aims In Phase II we intend to complete the development of PracticeGround using an agile development process to ensure usability and optimize workflow We will populate it with ESTs for depression insomnia bipolar disorder PTSD and suicide risk intervention and management loosely integrate PracticeGround into PracticeFusion and NetSmart using HL and develop a systems architecture design for tight integration of PracticeGround into EPIC PracticeFusion and NetSmart in Phase III We will conduct feasibility field tests at three sites that focus on usability and satisfaction frequencyof use across clients in their caseload and barriers to use We will then conduct an week randomized controlled trial N comparing PracticeGround n to care as usual n in depressed outpatient clients Primary outcomes include depression psychological distress treatment satisfaction clients and clinicians and treatment drop out Secondary clinician outcomes include extent of PracticeGround use with clients across cliniciansandapos caseload PUBLIC HEALTH RELEVANCE Our ultimate goal is to facilitate the delivery of empirically supported treatments ESTs for mental disorders and to improve client mental health outcomes Toward this end this Phase II SBIR proposal seeks to complete the development and testing of PracticeGround a comprehensive software system designed to integrate with electronic health records and that contains multiple methods of training clinicians in ESTs and delivering ESTs to clients continuous progress monitoring of client outcomes and clinical support tools to guide clinicians and clients through delivery of the necessary EST

SBIR

Phase II

2015

HHS

NIH